Summary

The goal of this proposal is to demonstrate the applications of a nanotechnology-based approach for the management of ‘wet’ AMD without using any toxic transfection reagents. In this approach, Dr. Uddin and colleagues will use gold nanoparticles engineered for the first time to treat AMD specific genes to overcome the limitations of existing therapy. They will test this new technology for its safety, high sensitivity, and specificity in cells and in animal models of ‘wet’ AMD. Using this novel nanotechnology, clinicians might be able to reduce specific diseased genes in AMD patients and could permanently reduce the risk of progression in a more timely fashion and preserving the vision.

Project Details

The goal of this proposed research is to demonstrate the application of a nanotechnology-based approach for the management of ‘wet’ AMD without using any toxic transfection reagents. In this approach, Dr. Uddin and colleagues will use gold nanoparticles engineered for the first time to treat AMD specific genes to overcome the limitations of existing therapy. They will test this new technology for its safety, high sensitivity, and specificity in cells and in animal models of ‘wet’ AMD. Using this novel nanotechnology, clinicians might be able to reduce specific diseased genes in AMD patients and could permanently reduce the risk of progression in a more timely fashion and preserving the vision.